APAC Artificial Insemination Market

APAC Artificial Insemination Market Size (2023 to 2028)

The size of artificial insemination in the APAC region was worth USD 0.48 billion in 2022. This value is further estimated to be growing at a CAGR of 10.99% from 2023 to 2028 and worth USD 0.95 billion by 2028 from USD 0.53 billion in 2023.

Increasing usage of home insemination kits due to increasing infertility in women is one of the primary factors driving the artificial insemination market forward in the Asia-Pacific region. This procedure is used for treating infertility. These Home insemination kits are given to couples with no chance of fertility and issue with intercourse. The success rate of pregnancy is higher when insemination is at home instead of in a fertility clinic. In addition, this kit is low cost compared to clinic treatment.

The growth of artificial insemination is further anticipated to be driven by increased animal productivity. Artificial insemination (AI) is used in many animal species for selective breeding, genetic improvement, and conservation. This process is mainly used in India because there is a shortage of high-quality males for cattle improvement. This process is primarily used in India because there is a shortage of high-quality males in cattle for cattle improvement; the technology of artificial insemination of livestock is beneficial. This method artificially introduces semen into the female reproductive system from select males. Artificial insemination is also used for reproductive success and for conserving threatened or endangered animals. In addition, AI helps prevent infectious or contagious diseases that can spread when animals are in one place. This procedure is used in dogs, goats, deer, buffalo, horses, beef, and sheep.

Growing infertility in India is contributing to the growth of the artificial insemination market in Asia-Pacific. World Health Organization estimated that between 3.9 and 16.8% of Indian women experience primary infertility. In India, infertility has gradually become a personal and public health issue. Infertility causes a lot of stress for the couple. The main reasons for Infertility in Indian people are driven by lifestyle changes, obesity, sexually transmitted infections, polycystic ovarian syndrome, fibroids, and genital tuberculosis in women. The success rates of artificial insemination per cycle differ between women based on age. Therefore, these people adopted this artificial insemination process for fertility which drives the market forward. Artificial insemination takes less time and is painless.

On the other hand, the process required well-trained people and sufficient equipment. Before going through this process in animals, the animal must be tested not to spread diseases to other animals. Improper cleaning and lack of proper sanitization also affect the market's growth. All these above factors act as a restraint to the market growth. Some symptoms include bloating, slight abdominal pain, dehydration, chest pain, shortness of breath, and possibly nausea and vomiting, which impede the market growth.

This research report on the APAC artificial insemination market has been segmented and sub-segmented into the following categories.

By Type:

• Intrauterine
• Intracervical
• Intravaginal
• Intratubal

By Source:

• AIH-Husband
• AID-Donor

By End-User:

• Hospitals and Clinics
• Fertility Centers
• Others

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

The Asia Pacific is expected to account for a promising share of the global market during the forecast period. Artificial insemination has no strict rules in India. But doctors follow some rules to do this treatment. Increasing awareness programs about artificial insemination also drive the market forward. For example, Assam has 1275 rural AI centers in the state for the need of dairy farmers. This government is providing better services by increasing the capacity of artificial insemination buildings, and in Assam, for only cattle breeding, there are 300 AI centers.

Artificial insemination in China increased in the last three years. According to the WHO, infertility is the third most serious disease worldwide. According to a recent study, 15% to 20% of the women of reproductive age in China suffer from infertility. In addition, China has a variety of technical requirements that provide the best treatment in hospitals and clinics. All these factors in China drive market growth.

KEY MARKET PLAYERS:

Rocket Medical, INVO Bioscience, Vitrolife, Pride Angel, Genea Limited, MedGyn Products, Inc., Rinovum Women's Health, Conceivex Inc., Tenderneeds Fertility, Hi-Tech Solutions, Fujifilm Irvine Scientific, and Kitazato Corporation are a few of the major companies operating in the APAC artificial insemination market and profiled in this report.